HUE049444T2 - Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen - Google Patents

Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen

Info

Publication number
HUE049444T2
HUE049444T2 HUE16712262A HUE16712262A HUE049444T2 HU E049444 T2 HUE049444 T2 HU E049444T2 HU E16712262 A HUE16712262 A HU E16712262A HU E16712262 A HUE16712262 A HU E16712262A HU E049444 T2 HUE049444 T2 HU E049444T2
Authority
HU
Hungary
Prior art keywords
mhc
eso
combined
gene therapy
cell receptor
Prior art date
Application number
HUE16712262A
Other languages
English (en)
Hungarian (hu)
Inventor
Thomas Blankenstein
Lucia Poncette
Xiaojing Chen
Original Assignee
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft
Publication of HUE049444T2 publication Critical patent/HUE049444T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16712262A 2015-03-13 2016-03-11 Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen HUE049444T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15159001.5A EP3067366A1 (en) 2015-03-13 2015-03-13 Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1

Publications (1)

Publication Number Publication Date
HUE049444T2 true HUE049444T2 (hu) 2020-09-28

Family

ID=52669528

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16712262A HUE049444T2 (hu) 2015-03-13 2016-03-11 Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen

Country Status (13)

Country Link
US (1) US10781243B2 (https=)
EP (3) EP3067366A1 (https=)
JP (2) JP6998211B2 (https=)
CN (2) CN114195883A (https=)
AU (1) AU2016232441B2 (https=)
CA (1) CA2974955A1 (https=)
DK (1) DK3268385T3 (https=)
ES (1) ES2784315T3 (https=)
HU (1) HUE049444T2 (https=)
PL (1) PL3268385T3 (https=)
PT (1) PT3268385T (https=)
SI (1) SI3268385T1 (https=)
WO (1) WO2016146505A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
AU2014343379B2 (en) 2013-11-04 2019-02-14 Uti Limited Partnership Methods and compositions for sustained immunotherapy
EP3291832B1 (en) 2015-05-06 2025-09-03 UTI Limited Partnership Nanoparticle compositions for sustained therapy
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3354658A1 (en) * 2017-01-25 2018-08-01 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2018185564A2 (en) * 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
CN109837245A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
TWI822726B (zh) * 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Ｎｙｅｓｏ ｔ細胞受體
CN110856751B (zh) 2018-08-24 2024-12-03 杭州康万达医药科技有限公司 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
EP3760217A1 (en) 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
US20220273714A1 (en) * 2019-07-19 2022-09-01 The Regents Of The University Of California T-cell receptors and methods of use thereof
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力t细胞受体
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
CN112501269B (zh) * 2020-12-15 2022-02-18 清华大学 一种快速鉴定高亲和力tcr抗原交叉反应活性的方法
CN114121142B (zh) * 2021-09-02 2023-10-31 四川大学华西医院 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060055A1 (en) * 1999-04-01 2000-10-12 The Brigham And Women's Hospital, Inc. Modified dendritic cells and uses therefor
WO2001055393A2 (en) * 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
ES2389251T3 (es) * 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
AU2003217384A1 (en) * 2002-02-13 2003-09-04 Ludwig Institute For Cancer Research Isolated peptides which bind to hla molecules and uses thereof
GB0411123D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd High-affinity NY-ESO T cell receptors
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
EP2852613B1 (en) * 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors
CA2899679C (en) 2013-01-29 2023-03-21 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
RU2578009C2 (ru) * 2013-05-08 2016-03-20 Закрытое акционерное общество "ЕВРОГЕН" Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
US11203783B2 (en) * 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis

Also Published As

Publication number Publication date
AU2016232441A1 (en) 2017-08-10
AU2016232441B2 (en) 2020-08-27
EP3268385A1 (en) 2018-01-17
EP3666793A3 (en) 2020-07-29
SI3268385T1 (sl) 2020-07-31
WO2016146505A1 (en) 2016-09-22
EP3268385B1 (en) 2020-01-08
CN107428816B (zh) 2022-01-14
CN107428816A (zh) 2017-12-01
CA2974955A1 (en) 2016-09-22
PT3268385T (pt) 2020-04-08
DK3268385T3 (da) 2020-04-06
ES2784315T3 (es) 2020-09-24
EP3666793A2 (en) 2020-06-17
EP3067366A1 (en) 2016-09-14
JP2021151249A (ja) 2021-09-30
HK1247212A1 (en) 2018-09-21
US10781243B2 (en) 2020-09-22
JP6998211B2 (ja) 2022-02-04
PL3268385T3 (pl) 2020-06-29
JP2018509163A (ja) 2018-04-05
US20180057560A1 (en) 2018-03-01
CN114195883A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
HUE049444T2 (hu) Rák kombinált T-sejt receptoros génterápiája a NY-ESO-1 tumorantigén MHC I és MHC II által korlátozott epitópjai ellen
IL294982B1 (en) nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
IL265759A (en) Therapeutic and diagnostic methods for cancer
EP3548048A4 (en) CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL255372A0 (en) Therapeutic and diagnostic methods for cancer
HUE061874T2 (hu) Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére
HUE059484T2 (hu) Az NY-ESO-1 tumorantigén - HLA-A
PL3532607T3 (pl) Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego
IL273071A (en) Treatment and diagnosis methods for cancer
IL250043A0 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3206987A4 (en) Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
IL248511A0 (en) Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
IL247066B (en) Cancer immunotherapy by combining local and systemic immune stimulation
PT3294770T (pt) Métodos terapêuticos e diagnósticos para o cancro
PT3142751T (pt) Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células.
ZA202102740B (en) Anti-liv1 immune cell cancer therapy
ZA202102745B (en) Anti-ptk7 immune cell cancer therapy
HUE043443T2 (hu) Monoklonális antitestek rák és autoimmun betegségek diagnosztizálásában és terápiájában történõ alkalmazásra
EP3271401A4 (en) Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
IL246607A0 (en) Improved cellular preparations and methods for cancer treatment
EP3146081A4 (en) Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
SG11201605784YA (en) Cell surface prostate cancer antigen for diagnosis
IL254228B (en) Cell therapeutic agent for cancer treatment and combination therapy with same
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy